123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma

Melzer, Henriette Ingrid; Coppenrath, Eva; Schmid, Irene; Albert, Michael H.; Schweinitz, Dietrich von; Tudball, Coral F.; Bartenstein, Peter; Pfluger, Thomas

doi:10.1007/s00259-011-1843-8

Cited by 79 publications

(46 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another study 123 I-MIBG scintigraphy and (18) F-FDG PET showed noticeable differences in their uptake patterns. 18 F-FDG PET was more sensitive and specific for the detection of neuroblastoma lesions [13] .…”

Section: Resultsmentioning

confidence: 95%

PET/CT and MIBG scans in diagnosis and management of Neuroblastoma

Fawzy

Moussa²,

Hamouda

et al. 2015

JST

View full text Add to dashboard Cite

Introduction and aim: Several studies report conflicting results about 18 F-FDG/PET and MIBG scans and their diagnostic as well as prognostic significance in children with neuroblastoma. The current study was meant to evaluate both modalities and to compare them in relation to standardized modes of evaluation. Results: FDG/PET showed good results in detecting NB at all sites. FDG/PET also showed a higher sensitivity and specificity, and a better PPV/NPV than MIBG which was not statistically significant. Concordance between paired scans (MIBG, and PET) was found in 55.7% of cases (Kappa=0.001) for primary tumor site, and in 7% for bone and 19.4% for bone marrow. The significance of concordance between both modalities was only demonstrated for metastatic boney lesions. There were 13 patients having stage III neuroblastoma (43.3%) while 17 patients (56.7%) were having stage IV disease. 23 Patients were categorized as high risk (76.7%) while 7 patients (23.3%) were intermediate risk. Both, PET/CT scan and MIBG were more sensitive in detecting disease at stage IV than stage III. Patients and Conclusion:18 F-FDG/PET scan can be used effectively in both diagnosis and management decisions for children with neuroblastoma, it is a good complementary tool especially in detecting bone metastasis, although further clinical trials must agree on definite analytical aspects between both modalities.

show abstract

Section: Resultsmentioning

confidence: 95%

PET/CT and MIBG scans in diagnosis and management of Neuroblastoma

Fawzy

Moussa²,

Hamouda

et al. 2015

JST

View full text Add to dashboard Cite

show abstract

“…Also, bone and bone marrow lesions could be masked or falsely interpreted as positive in patients receiving granulocyte colony-stimulating factor. In another study comparing 123 I-MIBG scintigraphy/SPECT and 18 F-FDG PET scan in pediatric neuroblastomas [ 57 ], the sensitivities were 50 and 78 % and the specifi cities were 75 and 92 %, respectively. The combined use of both modalities increased the sensitivity to 85 %.…”

Section: Imaging Featuresmentioning

confidence: 96%

Tumors of the Adrenal Gland

Kao

Pinto-Rojas

2014

Pediatric Malignancies: Pathology and Imaging

View full text Add to dashboard Cite

“…The role and timing of, for example, 18 They found a sensitivity of 50% with 123 I-mIBG versus 78% with 18 F-FDG PET and a specificity of 75% with 123 I-mIBG and 92% with 18 F-FDG PET. They concluded that 18 F-FDG PET may be a valuable imaging modality for patients with discrepant or inconclusive findings on 123 I-mIBG single photon emission CT/scintigraphy [39]. Sharp et al retrospectively compared 113 paired 123 I-mIBG and 18 F-FDG PET scans at diagnosis.…”

Section: Challenge 5 Disease Assessment and Response Assessmentmentioning

confidence: 98%

Ten Challenges in the Management of Neuroblastoma

et al. 2012

View full text Add to dashboard Cite

Neuroblastoma is a complex disease with many contradictions and challenges. It is, by and large, a cancer of babies and preschool children, but it does occur, albeit increasingly rarely, in older children, adolescents and young adults. The prognosis is very variable, with outcome related to age, stage and molecular pathology. Neuroblastoma may behave in an almost benign way, with spontaneous regression in some infants, but the majority of older patients have high-risk disease, which is usually fatal, despite best current treatments. As a rare disease, international collaboration is essential to run clinical trials of adequate statistical power to answer important questions in a reasonable time frame. High-risk disease requires multimodality therapy including chemotherapy, surgery and radiotherapy as well as biological and immunological treatments for optimal outcomes. Innovative treatment approaches, sometimes associated with appreciable toxicity, offer hope for the future but, despite parental wishes, cannot be generally implemented without adequate assessment in clinical trials.

show abstract

123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma

Cited by 79 publications

References 24 publications

PET/CT and MIBG scans in diagnosis and management of Neuroblastoma

PET/CT and MIBG scans in diagnosis and management of Neuroblastoma

Tumors of the Adrenal Gland

Ten Challenges in the Management of Neuroblastoma

Contact Info

Product

Resources

About